Jan 05, 2021
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Corporate
Jan 04, 2021
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Corporate
Oct 15, 2020
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests
Corporate
Sep 10, 2020
Myriad Genetics Expands Board of Directors with New Member
Corporate
Aug 14, 2020
Myriad Genetics Announces Inducement Awards
Corporate
Aug 13, 2020
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
Corporate
Aug 06, 2020
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
Corporate
Jul 22, 2020
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.
Corporate
May 28, 2020
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
Corporate
Apr 28, 2020
Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020
Corporate
Mar 23, 2020
Myriad Announces Board of Directors Leadership Transition
Corporate
Feb 12, 2020
Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
Corporate
Feb 06, 2020
Myriad Announces Leadership Transition
Corporate
Jan 30, 2020
Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020
Corporate
Jan 14, 2020
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
Corporate